not yet FDA-approved for any population Best adult efficacy / 24.2% mean weight loss at 48 weeks (12 mg dose, Phase 2) [1] Adolescent trial data / none published as of May 2026 Primary safety signals in adults / nausea, diarrhea, vomiting, decreased appetite [1] Growth concern / caloric restriction during puberty may slow linear growth velocity Mental-health watch / depression, suicidal ideation screening recommended per FDA adolescent obesity guidance Comparator precedent / semaglutide 2.4 mg studied in STEP TEENS (ages 12, 17) with a similar GI side-effect profile [2] Monitoring minimum / Tanner staging, height velocity, bone-age films, PHQ-A at each visit Why Adolescent Safety Data for Retatrutide Does Not Yet Exist No peer-reviewed trial has enrolled patients aged 12 to 17 for retatrutide as of May 2026
The APRN Compact is a multistate licensure agreement similar to the Nursing Licensure Compact (NLC) for RNs
Tea phenolics as prebiotics
How It Actually Feels (The Real Version) It is like it actually tells my body I was missing something in my brain that let me know like, oh, this is normal hunger
Where Pomegranate Health falls short The rigid refund policy is the most significant drawback
GHK-Cu is 71% of the blend by mass, so GLOW is best understood as a GHK-Cu protocol with two repair peptides layered in